TSA Updates Medical Cannabis Policy—But Offers No Actual Guidance

The Transportation Security Administration quietly revised its medical marijuana webpage on April 27 to list cannabis as permitted in carry-on and checked luggage, but the agency has yet to publish the "Special Instructions" it references for travelers attempting to comply.

The timing of the update—one day before cannabis officially moved to Schedule III under the Controlled Substances Act—has created confusion for medical patients and industry stakeholders trying to understand what, if anything, has changed at airport security checkpoints.

The TSA's Medical Marijuana page now categorizes cannabis products alongside items like prescription medications and medical devices, marking them as allowed with special handling requirements. Yet when travelers click for those requirements, they find nothing. The agency hasn't clarified what documentation patients need, which products qualify, or how state medical marijuana cards factor into federal screening procedures.

The Federal-State Disconnect

Cannabis remains illegal under federal law despite rescheduling, and airports operate under federal jurisdiction. Research indicates that Schedule III classification doesn't legalize marijuana—it simply acknowledges accepted medical use and lower abuse potential compared to Schedule I substances.

The Drug Enforcement Administration's rescheduling decision, which took effect April 28, permits physicians to prescribe cannabis products that meet FDA approval standards. Clinical evidence shows only three cannabis-derived medications currently hold that approval: Epidiolex, Marinol, and Syndros. None of these are the flower, concentrates, or edibles sold at state-licensed dispensaries.

This creates a practical paradox. State medical marijuana patients—numbering over 7 million across 38 programs—carry products that aren't federally recognized prescriptions, even though TSA now lists "medical marijuana" as permissible.

What TSA Screeners Actually Do

TSA's longstanding policy focuses on security threats, not drug enforcement. Screeners look for weapons and explosives, not cannabis. When they discover marijuana during bag checks, protocol requires them to refer the matter to local law enforcement.

But enforcement varies dramatically by location. Airports in cannabis-legal states like Denver and Los Angeles rarely prosecute possession cases. Connecting through Dallas or Atlanta presents different risks entirely, as Texas and Georgia maintain strict prohibition.

The agency hasn't indicated whether the webpage update signals any operational change in how screeners handle discovered cannabis products. Without published instructions, patients face the same uncertainty they did before April 27.

Industry Response and Unanswered Questions

Cannabis industry groups have pressed for clarity since the update appeared. Medical marijuana patients need to know whether state registry cards suffice as documentation, whether product labeling requirements exist, and what quantity limits apply.

Pharmacology research shows significant variation in cannabis product potency and formulation across state programs. A Florida medical card authorizes different products and THC concentrations than an Ohio card. TSA's lack of specificity leaves screeners with no standardized approach.

The update also doesn't address CBD products derived from hemp, which became federally legal under the 2018 Farm Bill. Those products already occupied a gray area at checkpoints, with enforcement depending on individual screener interpretation.

What Happens Next

TSA hasn't announced a timeline for publishing the promised special instructions. The agency typically coordinates such policy changes with the Department of Homeland Security and Department of Justice—a process that can take months.

Until formal guidance appears, medical cannabis patients face the same calculus they always have: weigh the legal risks of traveling with marijuana against medical necessity, and understand that state cards offer no federal protection.

The pharmaceutical industry continues developing FDA-approved cannabis medications, which would unambiguously qualify for air travel as prescription drugs. But those products remain years away from matching the variety and accessibility of state dispensary offerings that millions of patients currently rely on.

---

This article is based on original reporting by hightimes.com.